SFI
TXMD icon

Susquehanna Fundamental Investments’s TherapeuticsMD TXMD Stock Holding History

Susquehanna Fundamental Investments’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,619
Closed -$47.2K – 322
2023
Q3 		$47.2K Sell
15,619
-7,954
-34% -$30.1K ﹤0.01% 352
2023
Q2 		$97.1K Sell
23,573
-14,469
-38% -$56.8K ﹤0.01% 609
2023
Q1 		$143K Hold
38,042
– – ﹤0.01% 888
2022
Q4 		$213K Hold
38,042
– – ﹤0.01% 1059
2022
Q3 		$253K Buy
+38,042
New +$308K ﹤0.01% 1201

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna Fundamental Investments's TXMD Position: Q4 2023 in Review

Susquehanna Fundamental Investments sold out of TherapeuticsMD (TXMD) in Q4 2023, closing a stake of 15,619 shares — an estimated $47.2K sold.

Susquehanna Fundamental Investments first reported a position in TXMD in Q3 2022 and held it in 5 quarters. The position peaked at $253K in Q3 2022. 39 funds tracked by Wall St. Rank hold TXMD as of Q4 2023.

  • Susquehanna Fundamental Investments reported no remaining TherapeuticsMD position as of Q4 2023 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 15,619 TherapeuticsMD shares in Q4 2023, an estimated $47.2K.
  • Susquehanna Fundamental Investments first reported a position in TherapeuticsMD in Q3 2022 and held it in 5 quarters.
  • Susquehanna Fundamental Investments's TherapeuticsMD position peaked at $253K in Q3 2022.
  • 39 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2023, filed 14 Feb 2024.